Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:L01BB04
|
| gptkbp:CASNumber |
gptkb:4291-63-8
|
| gptkbp:chemicalFormula |
C10H12ClN5O3
|
| gptkbp:contraindication |
pregnancy
active malignancy |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:cladribine
|
| gptkbp:halfLife |
5-20 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mavenclad
|
| gptkbp:indication |
relapsing forms of multiple sclerosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_KGaA
|
| gptkbp:mechanismOfAction |
immunosuppressant
purine analog |
| gptkbp:pregnancyCategory |
X (contraindicated)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:lymphopenia
nausea headache infections |
| gptkbp:synonym |
gptkb:2-chlorodeoxyadenosine
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:默克
gptkb:Merck |
| gptkbp:bfsLayer |
5
|